In COVID-19 clinical update #82, Daniel Griffin reviews vaccines for 5-12 years old, safety of a third vaccine dose, Oklahoma reinfection data, Regencov outcomes, Pfizer protease inhibitor, impact of Tocilizumab, and incidence of long COVID.

Hosts: Daniel Griffin and Vincent Racaniello

Subscribe (free): iTunes, Google Podcasts, RSS, email

Become a patron of TWiV!

Links for this episode

• Data on Pfizer-BioNTech in 5-12 year olds (Pfizer)
• Safety of additional vaccine dose (MMWR)
• Oklahoma reinfection rates (OK DOH)
• Regencov outcomes (NEJM)
• Pfizer protease inhibitor trial (Pfizer)
• WHO recommends antibody therapy (Hosp Health)
• Tocilizumab use in hospitalized patients (Resp Care)
• Long COVID (PLoS Medicine)
• Letters read on TWiV 811
• Timestamps by Jolene. Thanks!

Intro music is by Ronald Jenkees Send your questions for Dr. Griffin to [email protected]